ketanserin has been researched along with Cirrhosis in 3 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Biliary fibrosis is a major complication after donation after cardiac death (DCD) liver transplantation." | 5.40 | Ketanserin, a serotonin 2A receptor antagonist, alleviates ischemia-related biliary fibrosis following donation after cardiac death liver transplantation in rats. ( Chen, G; Chen, L; Fan, W; Guo, Y; Liu, L; Qian, Y; Shi, B; Xiao, L, 2014) |
| "Biliary fibrosis is a major complication after donation after cardiac death (DCD) liver transplantation." | 1.40 | Ketanserin, a serotonin 2A receptor antagonist, alleviates ischemia-related biliary fibrosis following donation after cardiac death liver transplantation in rats. ( Chen, G; Chen, L; Fan, W; Guo, Y; Liu, L; Qian, Y; Shi, B; Xiao, L, 2014) |
| " Chronic administration of these antagonists strongly prevented exacerbation of ventricular hypertrophy in MAO-A KO mice." | 1.35 | Genetic deletion of MAO-A promotes serotonin-dependent ventricular hypertrophy by pressure overload. ( Bianchi, P; Calise, D; Escourrou, G; Galinier, M; Guilbeau-Frugier, C; Lairez, O; Mialet-Perez, J; Ordener, C; Parini, A; Pizzinat, N; Roncalli, J; Seif, I; Spreux-Varoquaux, O, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, L | 1 |
| Chen, G | 1 |
| Guo, Y | 1 |
| Liu, L | 1 |
| Xiao, L | 1 |
| Fan, W | 1 |
| Shi, B | 1 |
| Qian, Y | 1 |
| Chen, C | 1 |
| Han, X | 1 |
| Fan, F | 1 |
| Liu, Y | 1 |
| Wang, T | 1 |
| Wang, J | 1 |
| Hu, P | 1 |
| Ma, A | 1 |
| Tian, H | 1 |
| Lairez, O | 1 |
| Calise, D | 1 |
| Bianchi, P | 1 |
| Ordener, C | 1 |
| Spreux-Varoquaux, O | 1 |
| Guilbeau-Frugier, C | 1 |
| Escourrou, G | 1 |
| Seif, I | 1 |
| Roncalli, J | 1 |
| Pizzinat, N | 1 |
| Galinier, M | 1 |
| Parini, A | 1 |
| Mialet-Perez, J | 1 |
3 other studies available for ketanserin and Cirrhosis
| Article | Year |
|---|---|
Ketanserin, a serotonin 2A receptor antagonist, alleviates ischemia-related biliary fibrosis following donation after cardiac death liver transplantation in rats.
Topics: Animals; Biliary Tract Diseases; Cells, Cultured; Drug Evaluation, Preclinical; Fibroblasts; Fibrosi | 2014 |
Serotonin drives the activation of pulmonary artery adventitial fibroblasts and TGF-β1/Smad3-mediated fibrotic responses through 5-HT(2A) receptors.
Topics: Adventitia; Animals; Cell Proliferation; Connective Tissue Growth Factor; Extracellular Matrix; Fibr | 2014 |
Genetic deletion of MAO-A promotes serotonin-dependent ventricular hypertrophy by pressure overload.
Topics: Animals; Aorta; Blood Pressure; Cardiomegaly; Fibrosis; Fluorobenzenes; Gene Deletion; Gene Expressi | 2009 |